ストックスクリーナーアプリを入手
4.75
2.15%
0.10
アフターアワーズ：
4.75
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Why is Lexeo Therapeutics stock gaining Monday? - MSN
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst CallSlideshow (NASDAQ:LXEO) 2026-06-15 - Seeking Alpha
LXEO: Pivotal LX2006 trial in FA finalized, aiming for accelerated approval with strong early data - TradingView
Why Is Lexeo Therapeutics Stock Gaining Monday? - Benzinga
Lexeo finalizes pivotal trial design for gene therapy LX2006 By Investing.com - Investing.com South Africa
LXEO: Pivotal LX2006 trial in FA to start, targeting LVMI reduction with accelerated approval path - TradingView
Lexeo finalizes pivotal trial design for gene therapy LX2006 - Investing.com UK
2 Stocks To Watch Today Following Clinical Trial Updates - RTTNews
Lexeo Therapeutics (LXEO) Advances Gene Therapy Trial for Friedr - GuruFocus
Lexeo Therapeutics Finalizes SUNRISE-FA 2 Pivotal Trial Protocol And Statistical Analysis Plan For LX2006 Gene Therapy In Friedreich Ataxia - marketscreener.com
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy - TipRanks
Lexeo finalizes SUNRISE-FA 2 pivotal design for LX2006; topline data due 2H 2027, BLA targeted 1H 2028 - TradingView
Lexeo Therapeutics Announces Regulatory Update And Registrational Trial Design For LX2006 Gene Therapy In Friedreich Ataxia - TradingView
LXEO: Pivotal trial for LX2006 in Friedreich ataxia set for Q2 2026, targeting BLA in 2028 - TradingView
LXEO: Pivotal LX2006 study set for Q2 2026, aiming for accelerated approval and BLA in 1H 2028 - TradingView
Lexeo Therapeutics (Nasdaq: LXEO) maps LX2006 pivotal trial, 2027 data and 2028 BLA bid - Stock Titan
Gene therapy trial aims to tackle Friedreich ataxia heart damage - Stock Titan
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
LEXEO THERAPEUTICS INC (LXEO) Stock Chart - ChartMill
Lexeo Therapeutics (LXEO) Edges Higher, Holds Above Key Support After Modest GainPairs Trade - newsline.com
Cantor Fitzgerald Initiates Coverage of Lexeo Therapeutics (LXEO) with Overweight Recommendation - MSN
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Sahm
Lexeo Therapeutics (LXEO) Slips 2.29% as Stock Tests Key Support LevelsRSI Overbought Alerts - The Legal Advocate
Lexeo Therapeutics Q1 2026 Earnings: EPS Beat on Lower Operating CostsProfit Announcement - Newser
Lexeo Therapeutics (LXEO) Sees Mild Gains as Stock Holds Above Key SupportATR Trailing Stop - Newser
Top Executive Makes Notable Move in Lexeo Therapeutics Stock - TipRanks
Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction - Stock Titan
Lexeo Therapeutics (LXEO) Climbs +10.49% — Resistance at $5.20 in Focus 2026-05-20Retail Driven Moves - Newser
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Caledonian Record
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173 - Stock Titan
LXEO (NASDAQ: LXEO) lists restricted stock vesting; Form 144 shows past sale - Stock Titan
LXEO (NASDAQ: LXEO) insider sale notice — 1,595 vested shares - Stock Titan
4 spaces primed for the next wave of gene therapies - BioSpace
Paradigm BioCapital holds 6.18M Lexeo shares (LXEO); 8.3% stake reported - Stock Titan
Balyasny groups disclose 7.18M shares in Lexeo Therapeutics (LXEO) - Stock Titan
TradingKey - TradingKey
Lexeo Therapeutics, Inc. (LXEO) Eps Diluted (TTM) - Zacks Investment Research
Lexeo Therapeutics Price Target Maintained With a $17.00/Share by Chardan Capital - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Chardan Capital Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Forward-Looking Statements, and Key Disclosures - Minichart
Why Lexeo Therapeutics (LXEO) looks attractive at current levels (Parabolic) 2026-05-11Community Sell Signals - newser.com
Lexeo Therapeutics Reports Q1 2026 Results, Advances Cardiac Gene Therapy Pipeline, and Awaits FDA Feedback on Pivotal Trial - Minichart
Raymond James reiterates Strong Buy on Lexeo stock, $25 target By Investing.com - Investing.com Canada
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexeo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies - TipRanks
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights - The Manila Times
EDGAR Filing Documents for 0001193125-26-215674 - SEC.gov
Lexeo Therapeutics, Inc. 1Q 2026: Net income $(20.2M), EPS $(0.25) — 10-Q Summary - TradingView
Lexeo Therapeutics (NASDAQ: LXEO) posts lower Q1 loss with $227.6M cash - Stock Titan
Lexeo (Nasdaq: LXEO) trims Q1 loss and advances pivotal cardiac gene therapy plans - Stock Titan
Press Release: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights - Moomoo
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):